TriLink and Aldevron Collaborate to Enhance mRNA Manufacturing with CleanCap Solutions

  • TriLink BioTechnologies has signed a non-exclusive License and Supply Agreement with Aldevron, a CDMO specialising in plasmid DNA, RNA, and protein manufacturing.
  • The agreement enables Aldevron to utilise TriLink’s patented CleanCap mRNA capping technologies for preclinical through Phase III mRNA development and manufacturing.

TriLink BioTechnologies, a subsidiary of Maravai LifeSciences, has entered into a non-exclusive License and Supply Agreement with Aldevron, a global CDMO specialising in the production of plasmid DNA, RNA, and proteins. This partnership aims to expand access to TriLink’s CleanCap mRNA capping technologies for the development of mRNA-based therapeutics and vaccines.

Under the agreement, TriLink will supply its CleanCap M6, CleanCap AG 3’OMe, CleanCap AG, and CleanCap AU cap analogs for Aldevron’s mRNA manufacturing services. These technologies enable high-efficiency 5’Cap formation, improving mRNA yield and processing time compared to traditional capping methods. Aldevron will integrate these solutions across its development and manufacturing pipeline, from preclinical research to Phase III programs.

“CleanCap technology is accelerating programs through drug development milestones and has been the capping technology of choice for mRNA constructs in 350+ preclinical and clinical programs,” said Becky Buzzeo, Chief Commercial Officer, Maravai. “We’re excited to offer our innovative capping solutions to Aldevron and its manufacturing customers.”

TriLink launched CleanCap technology in 2017, and it has since become a leading capping solution used in most approved COVID-19 mRNA and saRNA vaccines. In 2023, the company introduced its latest cap analog, CleanCap M6, which has demonstrated over 30% increased mRNA expression compared to enzymatic capping methods.

Based in Fargo, North Dakota, Aldevron is a recognised leader in biological manufacturing, providing custom development and production services to support scientific innovation. Through this agreement, Aldevron will leverage TriLink’s capping solutions to further enhance its mRNA capabilities, supporting clients in advancing critical research and therapeutic programs.

Experience the future of contract manufacturing

Join us at CDMO Live, 7-8 May 2025 in Rotterdam for an exclusive live event dedicated to contract manufacturing partnerships. Apply for your ticket.

Sign up to our free weekly newsletter for all the latest contract manufacturing news.  Register here

Who do you rate?
Recommend a Supplier

Help us find the most innovative and trusted suppliers in Pharma and Biotech.